Literature DB >> 34378386

Design, Synthesis, and Biological Evaluation of Stable Colchicine-Binding Site Tubulin Inhibitors 6-Aryl-2-benzoyl-pyridines as Potential Anticancer Agents.

Hao Chen1, Shanshan Deng1, Najah Albadari1, Mi-Kyung Yun2, Sicheng Zhang1, Yong Li3, Dejian Ma1, Deanna N Parke4, Lei Yang3, Tiffany N Seagroves4, Stephen W White2, Duane D Miller1, Wei Li1.   

Abstract

We previously reported a potent tubulin inhibitor CH-2-77. In this study, we optimized the structure of CH-2-77 by blocking metabolically labile sites and synthesized a series of CH-2-77 analogues. Two compounds, 40a and 60c, preserved the potency while improving the metabolic stability over CH-2-77 by 3- to 4-fold (46.8 and 29.4 vs 10.8 min in human microsomes). We determined the high-resolution X-ray crystal structures of 40a (resolution 2.3 Å) and 60c (resolution 2.6 Å) in complex with tubulin and confirmed their direct binding at the colchicine-binding site. In vitro, 60c maintained its mode of action by inhibiting tubulin polymerization and was effective against P-glycoprotein-mediated multiple drug resistance and taxol resistance. In vivo, 60c exhibited a strong inhibitory effect on tumor growth and metastasis in a taxol-resistant A375/TxR xenograft model without obvious toxicity. Collectively, this work showed that 60c is a promising lead compound for further development as a potential anticancer agent.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34378386      PMCID: PMC9206500          DOI: 10.1021/acs.jmedchem.1c00715

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   8.039


  38 in total

1.  Preparation and properties of pure tubulin S.

Authors:  L Knipling; J Hwang; J Wolff
Journal:  Cell Motil Cytoskeleton       Date:  1999

2.  Studying drug-tubulin interactions by X-ray crystallography.

Authors:  Audrey Dorleans; Marcel Knossow; Benoît Gigant
Journal:  Methods Mol Med       Date:  2007

Review 3.  Current advances of tubulin inhibitors as dual acting small molecules for cancer therapy.

Authors:  Kinsie E Arnst; Souvik Banerjee; Hao Chen; Shanshan Deng; Dong-Jin Hwang; Wei Li; Duane D Miller
Journal:  Med Res Rev       Date:  2019-02-11       Impact factor: 12.944

Review 4.  An overview of tubulin inhibitors that interact with the colchicine binding site.

Authors:  Yan Lu; Jianjun Chen; Min Xiao; Wei Li; Duane D Miller
Journal:  Pharm Res       Date:  2012-07-20       Impact factor: 4.200

Review 5.  Recent Advances in Heterocyclic Tubulin Inhibitors Targeting the Colchicine Binding Site.

Authors:  Xiaoxin Wu; Qinghui Wang; Wei Li
Journal:  Anticancer Agents Med Chem       Date:  2016       Impact factor: 2.505

6.  Biological activity of 4-substituted methoxybenzoyl-aryl-thiazole: an active microtubule inhibitor.

Authors:  Chien-Ming Li; Zhao Wang; Yan Lu; Sunjoo Ahn; Ramesh Narayanan; Jeffrey D Kearbey; Deanna N Parke; Wei Li; Duane D Miller; James T Dalton
Journal:  Cancer Res       Date:  2010-11-16       Impact factor: 12.701

7.  Discovery of novel 2-aryl-4-benzoyl-imidazole (ABI-III) analogues targeting tubulin polymerization as antiproliferative agents.

Authors:  Jianjun Chen; Sunjoo Ahn; Jin Wang; Yan Lu; James T Dalton; Duane D Miller; Wei Li
Journal:  J Med Chem       Date:  2012-08-06       Impact factor: 7.446

8.  Features and development of Coot.

Authors:  P Emsley; B Lohkamp; W G Scott; K Cowtan
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2010-03-24

9.  Synthesis and biological evaluation of imidazo[2,1-b]thiazole-benzimidazole conjugates as microtubule-targeting agents.

Authors:  Mirza Feroz Baig; V Lakshma Nayak; Prasad Budaganaboyina; Kishore Mullagiri; Satish Sunkari; Jitendra Gour; Ahmed Kamal
Journal:  Bioorg Chem       Date:  2018-02-12       Impact factor: 5.275

10.  Standardization of A375 human melanoma models on chicken embryo chorioallantoic membrane and Balb/c nude mice.

Authors:  Stefana Avram; Dorina-Elena Coricovac; Ioana Zinuca Pavel; Iulia Pinzaru; Roxana Ghiulai; Flavia Baderca; Codruta Soica; Danina Muntean; Daciana E Branisteanu; Demetrios A Spandidos; Aristides M Tsatsakis; Cristina Adriana Dehelean
Journal:  Oncol Rep       Date:  2017-05-22       Impact factor: 3.906

View more
  4 in total

1.  Design, Synthesis, and Biological Evaluation of Apcin-Based CDC20 Inhibitors.

Authors:  Rajib Bhuniya; Xinrui Yuan; Longchuan Bai; Kathryn L Howie; Rui Wang; Wei Li; Frank Park; Chao-Yie Yang
Journal:  ACS Med Chem Lett       Date:  2022-01-18       Impact factor: 4.345

2.  Colchicine-Binding Site Agent CH-2-77 as a Potent Tubulin Inhibitor Suppressing Triple-Negative Breast Cancer.

Authors:  Shanshan Deng; Raisa I Krutilina; Kelli L Hartman; Hao Chen; Deanna N Parke; Rui Wang; Foyez Mahmud; Dejian Ma; Pradeep B Lukka; Bernd Meibohm; Tiffany N Seagroves; Duane D Miller; Wei Li
Journal:  Mol Cancer Ther       Date:  2022-07-05       Impact factor: 6.009

3.  Discovery of Putative Dual Inhibitor of Tubulin and EGFR by Phenotypic Approach on LASSBio-1586 Homologs.

Authors:  Gisele Barbosa; Luis Gabriel Valdivieso Gelves; Caroline Marques Xavier Costa; Lucas Silva Franco; João Alberto Lins de Lima; Cristiane Aparecida-Silva; John Douglas Teixeira; Claudia Dos Santos Mermelstein; Eliezer J Barreiro; Lidia Moreira Lima
Journal:  Pharmaceuticals (Basel)       Date:  2022-07-23

4.  Design, Synthesis and Biological Investigation of 2-Anilino Triazolopyrimidines as Tubulin Polymerization Inhibitors with Anticancer Activities.

Authors:  Romeo Romagnoli; Paola Oliva; Filippo Prencipe; Stefano Manfredini; Federica Budassi; Andrea Brancale; Salvatore Ferla; Ernest Hamel; Diana Corallo; Sanja Aveic; Lorenzo Manfreda; Elena Mariotto; Roberta Bortolozzi; Giampietro Viola
Journal:  Pharmaceuticals (Basel)       Date:  2022-08-21
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.